A Multicenter, Multinational, Observational Morquio A Registry Study (MARS)
A legfontosabb adatok
- Ki végzi
- BioMarin Pharmaceutical
- Hol
- Ann Arbor, Boston, Chicago, Decatur, Durham, Honolulu, Houston, Iowa City, Las Vegas, Little Rock, Los Angeles, Louisville, Miami, Milwaukee, Minneapolis, Morristown, New York, Norfolk, Orange, Philadelphia, Phoenix, Pittsburgh, Seattle, Washington D.C. és Wilmington (Egyesült Államok)Mind a 26 helyszín megnézéseMég 16 másik országban, 53 helyszínen
- Azonosító
- Állapot
- Befejeződött
- Résztvevők
- 418 fő vett részt
- Kezdés
- 2014. szept.
- Befejezés
- 2024. febr. 21.
- A vizsgálat típusa
- Megfigyeléses
- A vizsgált kezelések
- Vimizim® (elosulfase alfa)
- A regiszteradat frissítve
- 2024. március 5.
Ki vehet részt
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 13 feltétel megnézéseKevesebb
Ki vehet részt
- Patients eligible to participate in this Registry must meet all of the following criteria:
- Diagnosed with MPS IVA as confirmed by either N-acetylgalactosamine 6-sulfatase (GALNS) enzymatic test or by a diagnostic molecular test
- Willing and able to provide written, signed informed consent, or, in the case of patients age < 18 years, provide written assent (if required) and written informed consent, signed by a legally authorized representative after the nature of the Registry has been explained and prior to performance of any Registry-related procedures
- Willing to undergo assessments to establish baseline data or permit Investigator to enter assessment data recorded prior to Registry entry if available in the patient's medical records. Entry assessments may include: demographics, medical history, urinary keratan sulfate level, urinary protein level, immunogenicity testing, vital signs, physical examination, and height and weight; Patients eligible to participate in the Registry Substudy for MOR-005 must meet all of the following criteria:
- Must have completed the MOR-005 clinical trial
- Willing and able to provide written, signed informed consent, or, in the case of patients age < 18 years, provide written assent (if required) and written informed consent by a legally authorized representative after the nature of the Registry Substudy has been explained and prior to any Registry-related Substudy procedures
- Willing to permit Investigator to enter assessment data recorded prior to Registry
- Substudy entry if available in the patient's medical records; Patients eligible to participate in this Registry Substudy for MOR-007 must meet all of the following criteria:
- Must have completed the MOR-007 clinical trial
- Willing and able to provide written, signed informed consent, or in the case of patients age < 18 years, provide written assent (if required) and written informed consent by a legally authorized representative after the nature of the Registry Substudy has been explained, and prior to any Registry-related Substudy procedures
- Willing to permit Investigator to enter assessment data recorded prior to Registry Substudy entry if available in the patient's medical records
Ki nem vehet részt
- Patients who meet the following exclusion criterion will not be eligible to participate in the Registry or Registry Substudies:
- Patients currently participating in a BMN 110 (elosulfase alfa) clinical trial
Helyszínek itt: Egyesült Államok
Még 16 másik országban, 53 helyszínen
- University of MichiganAnn Arbor, Egyesült Államok
- Children's Hospital of BostonBoston, Egyesült Államok
- Ann & Robert H. Lurie Children's HospitalChicago, Egyesült Államok
- Emory UniversityDecatur, Egyesült Államok
- Duke University Medical CenterDurham, Egyesült Államok
- Kapiolani Medical Center for Women and ChildrenHonolulu, Egyesült Államok
- UTHealth McGovern Medical SchoolHouston, Egyesült Államok
- University of IowaIowa City, Egyesült Államok
- Children's Specialty Center of NevadaLas Vegas, Egyesült Államok
- Arkansas Children's HospitalLittle Rock, Egyesült Államok
- Children's Hospital of Los AngelesLos Angeles, Egyesült Államok
- University of Southern CaliforniaLos Angeles, Egyesült Államok
- University of Louisville Research Foundation Inc./Kosair Charities Pediatric Clinical Research UnitLouisville, Egyesült Államok
- Miami Children's HospitalMiami, Egyesült Államok
- Children's Hospital of WisconsinMilwaukee, Egyesült Államok
- Children's Hospitals and Clinics of MinnesotaMinneapolis, Egyesült Államok
- Atlantic Health SystemMorristown, Egyesült Államok
- NYU-Langone Medical Center School of MedicineNew York, Egyesült Államok
- Children's Hospital of The King's DaughtersNorfolk, Egyesült Államok
- Children's Hospital of Orange CountyOrange, Egyesült Államok
- Children's Hospital of PhiladelphiaPhiladelphia, Egyesült Államok
- Phoenix Children s HospitalPhoenix, Egyesült Államok
- Children's Hospital of Pittsburgh of UPMCPittsburgh, Egyesült Államok
- Seattle Children's HospitalSeattle, Egyesült Államok
- Children's National Health SystemWashington D.C., Egyesült Államok
- A.I. duPont Hospital for ChildrenWilmington, Egyesült Államok
A vizsgálatról
Mit akar kideríteni a vizsgálat
The objectives of this program are: to characterize and describe the Mucopolysaccharidosis IV type A (MPS IVA) population as a whole, including the heterogeneity, progression, and natural history of MPS IVA; to evaluate the long-term effectiveness and safety of Vimizim®, including, but not limited to, the occurrence of serious hypersensitivity reactions, anaphylaxis, and changes in antibody status; to help the medical community with the development of recommendations for monitoring MPS IVA patients and reports on patient outcomes to optimize patient care; to collect data on other treatment paradigms, and evaluate the prevalences of their use and their effectiveness; to characterize the effects and safety of Vimizim treatment 5 years from enrollment in the Registry for patients under 5 years of age; to monitor pregnancy exposure, including maternal, neonatal, and infant outcomes; and to monitor patients who have completed the MOR-005 and MOR-007 clinical trials. These patients will be encouraged to enroll in the applicable Registry Substudy and will be monitored using the MOR-005 and MOR-007 assessment schedules, respectively.
A vizsgált kezelések
- Vimizim® (elosulfase alfa)
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- A regiszteradat frissítve
- 2024. március 5.